Molecure - An important year for R&D approaches
In Molecure’s recent R&D day presentation, management highlighted the progress of OATD-01 and OATD-02 as the company prepares to begin important clinical trials for sarcoidosis and solid tumours, respectively, in 2023. Details from the presentation show Molecure is planning to maximise the potential of both assets, in our view. Pre-clinical animal model data for OATD-01 suggest it could have potential use in non-alcoholic steatohepatitis (NASH), a fibrotic disease with unmet needs, however we note that animal data is not generalisable to humans. Further, the trial design for the upcoming Phase I study for OATD-02 confirms the company will target cancers where immune checkpoint inhibitors (ICIs) have had limited success, an area where we believe OATD-02/ICI combinations could have an impact. In our view, this is supportive of Molecure’s development strategy as the company approaches key trial initiations in 2023.OncoArendi Therapeutics SA (OAT) is a Poland-based biopharmaceutical company dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Companys business model is strictly focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations with the key opinion leaders in specific disease areas.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.